Potential Mortality Reduction with Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure in Mexico

PARADIGM-HF, a phase III trial conducted in patients with heart failure (HF), showed that sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor for treatment of HF with reduced ejection fraction (HFrEF), provided incremental cardiovascular and overall survival benefit compared with enalapril. This analysis aims to quantify the number of all-cause deaths that could be avoided with optimal usage of sacubitril/valsartan in the treatment of HFrEF in Mexico.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research